AbCellera is a Canadian biotechnology company headquartered in Vancouver, built around a proprietary antibody discovery platform that it licenses to pharmaceutical and biotech partners developing new drug candidates. Listed on Nasdaq under the ticker ABCL.O, the company gained widespread recognition during the COVID-19 pandemic as the discoverer of bamlanivimab, an antibody treatment developed in partnership with Eli Lilly and Company, which brought both revenue and visibility to a business that had previously operated largely below mainstream investor radar.
The underlying business model is distinctive: rather than advancing drugs through the full clinical pipeline itself, AbCellera acts as an upstream discovery partner, taking royalties and milestones as its partners progress candidates towards commercialisation. That royalty-driven structure gives the company long-term revenue potential largely decoupled from the operational complexity of running clinical trials, though near-term income can be lumpy and heavily dependent on partner development timelines.
Please note this is marketing communication, not recommendation or advice.
client accounts
FxPro has been providing online trading services to clients since 1999 and it currently serves 173 countries worldwide.
Awards
FxPro has received constant recognition in the industry, winning over 145 international awards to date for the quality of its services.
customer service
Our dedicated, multilingual customer service team works 24/5 to provide you with an exceptional level of support.
industry regulations
FxPro operates under strict regulatory oversight across multiple jurisdictions, including authorisation by the FCA in the UK — one of the most trusted financial regulators globally.
